Format

Send to

Choose Destination
Arch Esp Urol. 1995 Dec;48(10):979-83.

[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].

[Article in Spanish]

Author information

1
Servicio de Urología, Hospital Principe de Asturias, Facultad de Medicina, Universidad de Alcalá de Henares, Madrid.

Abstract

OBJECTIVES:

The present study describes two patients with retroperitoneal fibrosis following prolonged use of bromocriptine and pergolide for Parkinson's disease. Both patients also presented severe atheromatosis.

METHODS:

Similar cases reported in the literature are reviewed and the possible relationship between the use of the ergotamine derivate and severe atheromatosis is discussed.

RESULTS:

Both patients, a 67-year-old male and a 62-year-old female, improved after discontinuing bromocriptine, despite severe damage of renal function.

CONCLUSIONS:

Retroperitoneal fibrosis may develop in patients with bilateral ureteral obstruction, especially those who have received drugs that have been reported to cause the foregoing condition.

PMID:
8588730
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center